Vol 54, No 4 (2020)
Invited Editorial
Published online: 2020-08-31

open access

Page views 755
Article views/downloads 1022
Get Citation

Connect on Social Media

Connect on Social Media

Sexual dysfunction in Huntington’s Disease: what do we really know?

Philip W. Tipton1
Pubmed: 32870497
Neurol Neurochir Pol 2020;54(4):291-293.

Abstract

Introduction. In this edition, Szymuś et al. conducted a systematic review revealing sexual dysfunction to be more prevalent in patients with Huntington’s Disease compared to controls.

Clinical reflections. Sexual dysfunction in HD (SDHD) is common and significantly affects patient quality of life. Commonly used HD rating scales and treatment guidelines do not explicitly address SDHD, and research studies are limited by size and methodology.

Clinical implications. It is important that validated sexual dysfunction screening tools be utilised in clinical and research
settings.

Article available in PDF format

View PDF Download PDF file

References

  1. Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983; 306(5940): 234–238.
  2. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet. 1994; 31(11): 872–874.
  3. Roos RAC. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010; 5: 40.
  4. Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012; 27(9): 1083–1091.
  5. Glidden AM, Luebbe EA, Elson MJ, et al. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020 [Epub ahead of print].
  6. Szymuś K, Bystrzyński A, Kwaśniak-Butowska M, et al. Sexual dysfunction in Huntington's Disease - a systematic review. Neurol Neurochir Pol. 2020 [Epub ahead of print].
  7. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). SpringerReference. .
  8. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11(2): 136–142.
  9. Winder JY, Achterberg WP, Marinus J, et al. Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP. Mov Disord Clin Pract. 2018; 5(5): 527–533.
  10. Youssov K, Dolbeau G, Maison P, et al. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study. Mov Disord. 2013; 28(14): 1995–2001.
  11. Armstrong MJ, Miyasaki JM. Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease. 2012. www.neurology.org (27.03.2020).
  12. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6): 822–830.
  13. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2): 191–208.
  14. Simpson JA, Lovecky D, Kogan J, et al. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs. J Huntingtons Dis. 2016; 5(4): 395–403.
  15. Kolenc M, Kobal J, Podnar S. Male sexual function in presymptomatic gene carriers and patients with Huntington's disease. J Neurol Sci. 2015; 359(1-2): 312–317.
  16. Kolenc M, Kobal J, Podnar S. Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington’s Disease. J Huntingtons Dis. 2017; 6(2): 105–113.
  17. Aldaz T, Nigro P, Sánchez-Gómez A, et al. Non-motor symptoms in Huntington's disease: a comparative study with Parkinson's disease. J Neurol. 2019; 266(6): 1340–1350.
  18. Aziz NA, Anguelova GV, Marinus J, et al. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. Eur J Neurol. 2010; 17(8): 1068–1074.
  19. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016; 17(18): 2461–2470.
  20. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007; 22(2): 193–197.
  21. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002; 36(10): 1577–1589.
  22. Mirek E, Filip M, Chwała W, et al. The influence of motor ability rehabilitation on temporal-spatial parameters of gait in Huntington's disease patients on the basis of a three-dimensional motion analysis system: An experimental trial. Neurol Neurochir Pol. 2018; 52(5): 575–580.
  23. Leavitt B, Kordasiewicz H, Schobel S. Huntingtin-Lowering Therapies for Huntington Disease. JAMA. 2020.
  24. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Phase 1–2a IONIS-HTTRx Study Site Teams. Targeting Huntingtin Expression in Patients with Huntington's Disease. N Engl J Med. 2019; 380(24): 2307–2316.



Neurologia i Neurochirurgia Polska